The Drug-Induced Respiratory Disease Website
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXIX. Small airway involvement
XXIX.d Cough (lone)
XXXVIII. Miscellaneous - Varia
XXXVIII.k Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.a Cardiac arrhythmias or dysrhythmias (AF, VT, VF, TdP)
I. Cardiac arrhythmia(s)/dysrhythmia(s) (AF, VT, VF, TdP) - QTc prolongation)
I.g QTc prolongation
II. Myocardial dysfunction - Heart failure
II.c Heart failure (biventricular, congestive)
VII. Cardiotoxicity
VII.a ‘Cardiotoxicity’
XVI. Hemorrhage - Bleeding - Hematoma(s)
XVI.e Alveolar hemorrhage (AH), diffuse AH (DAH)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.c Eosinophilic pneumonia (pulmonary infiltrates and eosinophilia)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.m Subclinical pulmonary infiltrates/ILD
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.u Transient pulmonary opacities/infiltrates (TAPO)
XXXIX. Rechallenge
XXXIX.a Rechallenge can lead to near-fatal or fatal relapse of AE/ILD
XXXIX. Rechallenge
XXXIX.e Rechallenge may not lead to relapse of the AE/ILD
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)
XXXVIII. Miscellaneous - Varia
XXXVIII.k Hypersensitivity reaction (may manifest with fever and/or skin, throat or airway involvement)
II. Myocardial dysfunction - Heart failure
II.a Left ventricular dysfunction/failure
X. Pulmonary edema
X.b Pulmonary edema, noncardiogenic (NCPE)
XXVIII. Large airway involvement
XXVIII.a Angioedema (may cause UAO, asphyxia and death)
XXIX. Small airway involvement
XXIX.a Bronchospasm - Wheezing - Asthma
XXIX. Small airway involvement
XXIX.j Bronchospasm and angioedema
XXXVI. Autoimmune syndromes - Systemic reactions or conditions
XXXVI.f Anaphylaxis - Anaphylactoid reaction (either of these can be fatal)
XII. Pericardial involvement
XII.c Hemopericardium - Bloody pericardial effusion
XIII. Thrombosis - Embolism
XIII.a Pulmonary embolism - Venous thrombosis/thrombo-embolism
XIV. Pleural involvement
XIV.e Hemothorax - Serosanguineous pleural effusion
XIV. Pleural involvement
XIV.f Pneumothorax
XVII. Heart injury/trauma/perforation
XVII.a Perforation of the heart - Cardiac rupture
XXXVIII. Miscellaneous - Varia
XXXVIII.t Venous thoracic outlet syndrome
XXII. Acute respiratory/cardiorespiratory failure
XXII.b Acute lung injury - ARDS
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.b Pneumonitis (ILD), acute and/or severe (may cause ARDS)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.a Pneumonitis (ILD)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.h Pulmonary fibrosis (may improve but partly following drug discontinuation)
XXIV. Interstitial lung disease - Pulmonary infiltrates - Pulmonary fibrosis
XXIV.y Exogenous lipoid pneumonia (subacute, acute)
XXX. Imaging features
XXX.z Imaging: Intrathoracic lymph node enlargement
XXX. Imaging features
XXX.aa Lipid-laden mediastinal lymphadenopathy
XXX. Imaging features
XXX.ab Imaging: Diffuse haze